BB Biotech AG reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was CHF 220.99 million. Net income was CHF 210.28 million compared to net loss of CHF 208.4 million a year ago. Basic earnings per share from continuing operations was CHF 3.83 compared to basic loss per share from continuing operations of CHF 3.76 a year ago. Diluted earnings per share from continuing operations was CHF 3.83 compared to diluted loss per share from continuing operations of CHF 3.76 a year ago.
For the nine months, revenue was CHF 1.26 million compared to CHF 187.17 million a year ago. Net loss was CHF 322.65 million compared to net income of CHF 141.1 million a year ago. Basic loss per share from continuing operations was CHF 5.86 compared to basic earnings per share from continuing operations of CHF 2.55 a year ago. Diluted loss per share from continuing operations was CHF 5.86 compared to diluted earnings per share from continuing operations of CHF 2.55 a year ago.